News

Video

Education and Resources for Patients with GVHD

The panel highlights the importance of a multidisciplinary approach and best practices in education for patients with GVHD.

Transcript:

Bonnie J. Dirr, APRN:Thank you. Dr Inyang, I know that you really helped to develop this program in role with a collaborative team. In terms of your patients and our patients that we share, you always tend to further put forth and make sure that patients [have] the ability…to understand what their actual diagnosis is. In terms of resources, I know that you always make yourself available to our patients and families, which is wonderful. But what other type of materials at the Dana-Farber do you provide for your patients as they sit with you during an exam visit or an educational session?

Eno-Abasi Inyang, PharmD, BCPS, BCOP: Yeah, that’s a great question, and I think it’s a really important one because it’s something that we strive to do at the Dana-Farber, making sure patients have access to anyone and anything that can help them get through this difficult situation. One of the things that we love to do is, we have teaching sheets that we make for patients. We give our patients teaching sheets on all their chemotherapy medications. We give teaching sheets on any of their specialty medications that they receive. It goes through some of the highlights in terms of frequently asked questions. I usually review this with them prior to giving it to them. They always have that as a resource. We love to make the medication binders as well. We usually list out all their home medications as well as the medications they’re taking. We list what the indication is, and we go over it and provide them that contact information. Then as well as medication teaching sheets, we usually give them access to different websites that they can go to, things like cancer.gov and so forth that are more patient friendly. If they have any questions or want to read up on anything, they can, and then we always just tell them, please reach out if any questions come up, we’re here for you at any time.

Bonnie J. Dirr, APRN: Thank you, Dr Inyang. And thank you, Dr Gooptu. You know, it’s wonderful to hear you each point out each of the pieces of information. We really do strive for a multidisciplinary look at things, in the teaching sheets and the binders that have been developed. It also gives us a resource in terms of involving the nurses that are at our bedside with infusion patients, have them available should they need to be hospitalized. We really thank you both. Specifically, Dr Inyang, in the development of the educational piece of things for our patients and families. It really has been an integral role for how it is that we’ve advanced our care here at the Dana-Farber. Thank you.

Transcript is AI-generated and edited for clarity and readability.

Related Videos
3 experts are featured in this series.
2 experts in this video
2 experts in this video
Ashkan Emadi, MD, PhD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
2 experts in this video